Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
about
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerCIViC databaseImpact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancerKRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing.Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNACorrelation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer.KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer.ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT.Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastasesGenomic classification of the RAS network identifies a personalized treatment strategy for lung cancerPrognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasA Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element.Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancersNatural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.Thymic neoplasm: a rare disease with a complex clinical presentationA randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapiesPoor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.Postrecurrence survival of surgically resected pulmonary adenocarcinoma patients according to EGFR and KRAS mutation status.Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC.An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer.Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancerCytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations.Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic Non-Small Cell Lung Carcinoma (NSCLC).KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.Regression of an intramedullary spinal cord metastasis with a checkpoint inhibitor: a case report.
P2860
Q26865779-29F18A3C-3BF3-47ED-BF35-FC839EDD4A5EQ27612411-4A017C1C-991F-4CA7-A284-5A50EE32256BQ27853180-9C505FE5-518D-44E0-A7AF-480914FDD6E0Q33634165-4976B7FD-1160-4D0A-966A-4CBE317F0417Q33648808-CFFFB6B5-E5C1-460D-9871-75ECC99A1C7CQ33737740-1A67FB6A-E554-48B7-A037-822883E5B233Q33857652-DB307FB6-C44B-4C46-850E-F64FEA3D9761Q33878516-F4726A46-EADB-4E1C-813E-4F76FD7946BAQ33909660-F33E18B7-B32B-4D39-9269-74320F2799C1Q34723950-F0D0F440-2710-400E-AA2F-9CB2E44A95D9Q34886787-88C30AAD-1D4D-4D8B-8FB5-543B161A9313Q35670290-8A1763B7-A959-475E-8A96-3EB50B33E187Q35775729-288F6E46-C825-46A3-92B9-676A69EF70ADQ36197300-6AF44C17-76DA-459E-8ECF-339465A1A708Q36501975-96AE6901-5DED-4A2E-9D73-C5FCC321C28CQ36547123-8FFD64C2-E6B4-43B7-B18A-AD25B619F937Q36557569-8655426D-5B7F-4401-8851-B59F07584724Q36666814-DE301D12-71D2-4E1D-ABB8-E49BA735E601Q36750622-5BAFD195-CE63-4529-986A-EE1ADD349A49Q36753888-92AA0AF0-FE06-41E0-AACF-2234640CBCA6Q36865033-35B3CE59-85DF-4636-9991-0891EB5E3F2CQ36946809-86C1BB8D-C360-4328-B874-5F2F226C600AQ37067360-1B591262-26C9-48FA-87A9-DA34A3947B70Q37146779-ABAF7420-F13B-436F-837D-E1FD7DA381D8Q37528486-B1ED7500-A8B3-4735-9CBC-41AD6100C73EQ37567804-A1CECFD5-23A7-4D1F-9126-E89D3338A03AQ37646889-D0CB33CC-A6D2-4923-A4F1-FB40473B0B4BQ37673912-8E7B10CC-1FB5-49CA-8C9C-949FFAD5C1B8Q37699284-6C33B0BF-741F-43B3-B46C-D2514DB76051Q37701159-C64DEAA8-01E6-4DA0-B8AC-FDF203D1AC53Q38271717-23DA92D7-926F-4559-8837-826A976A25DEQ38358410-138115CF-6455-4D74-93DE-5B0EFC7CB616Q38390200-42EBD21D-860D-416D-BA00-6D22D4F26C62Q38682370-7629C62C-B2AF-4D81-A136-93039F2EDD37Q38792704-BB52A688-D0FD-4967-93FE-68F831C56BCCQ38903804-9F93B986-37DC-458B-88E3-66B2756029B6Q40185703-09AD1840-8CC7-40DB-8275-1E060FF4CBDBQ40542208-09AE7AFA-60F7-4A7F-8F52-1693910645BEQ42340129-001421CF-47A7-49E0-B33F-BB3AED2CED7AQ45070164-A0743F0E-7C6F-4D85-A123-6D01ADC41272
P2860
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Association of KRAS and EGFR m ...... advanced lung adenocarcinomas.
@ast
Association of KRAS and EGFR m ...... advanced lung adenocarcinomas.
@en
Association of KRAS and EGFR m ...... advanced lung adenocarcinomas.
@nl
type
label
Association of KRAS and EGFR m ...... advanced lung adenocarcinomas.
@ast
Association of KRAS and EGFR m ...... advanced lung adenocarcinomas.
@en
Association of KRAS and EGFR m ...... advanced lung adenocarcinomas.
@nl
altLabel
Association ofKRASandEGFRmutat ...... advanced lung adenocarcinomas
@en
prefLabel
Association of KRAS and EGFR m ...... advanced lung adenocarcinomas.
@ast
Association of KRAS and EGFR m ...... advanced lung adenocarcinomas.
@en
Association of KRAS and EGFR m ...... advanced lung adenocarcinomas.
@nl
P2093
P2860
P356
P1433
P1476
Association of KRAS and EGFR m ...... advanced lung adenocarcinomas.
@en
P2093
Camelia S Sima
Gregory J Riely
Jamie Chaft
Mark G Kris
Melissa L Johnson
Paul K Paik
P2860
P304
P356
10.1002/CNCR.27730
P407
P577
2013-01-15T00:00:00Z